This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albrecht, M. T.
Right arrow Articles by Baillie, L. W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albrecht, M. T.
Right arrow Articles by Baillie, L. W. J.

 Previous Article  |  Next Article 

Infection and Immunity, November 2007, p. 5425-5433, Vol. 75, No. 11
0019-9567/07/$08.00+0     doi:10.1128/IAI.00261-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Human Monoclonal Antibodies against Anthrax Lethal Factor and Protective Antigen Act Independently To Protect against Bacillus anthracis Infection and Enhance Endogenous Immunity to Anthrax{triangledown}

Mark T. Albrecht,1* Han Li,2 E. Diane Williamson,3 Chris S. LeButt,3 Helen C. Flick-Smith,3 Conrad P. Quinn,2 Hans Westra,4 Darrell Galloway,5 Alfred Mateczun,1 Stanley Goldman,1 Herman Groen,4,6 and Les W. J. Baillie7

Biological Defense Research Directorate, Naval Medical Research Center, Silver Spring, Maryland 20910-7500,1 MPIR Laboratory, Meningitis & Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control & Prevention, Atlanta, Georgia,2 Defense Science Technology Laboratories, Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom,3 IQ Corporation, Rozenburglaan 13a, 9727 DL Groningen, The Netherlands,4 The Ohio State University, Department of Microbiology, Columbus, Ohio 43210,5 University of Groningen, University Medical Center, Department of Pathology and Laboratory Medicine, Medical Biology Section, Laboratory for Tumor Immunology, Groningen, The Netherlands,6 Cardiff University, Welsh School of Pharmacy, Cardiff CF10 3NB, Wales, United Kingdom7

Received 16 February 2007/ Returned for modification 6 April 2007/ Accepted 7 June 2007

The unpredictable nature of bioterrorism and the absence of real-time detection systems have highlighted the need for an efficient postexposure therapy for Bacillus anthracis infection. One approach is passive immunization through the administration of antibodies that mitigate the biological action of anthrax toxin. We isolated and characterized two protective fully human monoclonal antibodies with specificity for protective antigen (PA) and lethal factor (LF). These antibodies, designated IQNPA (anti-PA) and IQNLF (anti-LF), were developed as hybridomas from individuals immunized with licensed anthrax vaccine. The effective concentration of IQNPA that neutralized 50% of the toxin in anthrax toxin neutralization assays was 0.3 nM, while 0.1 nM IQNLF neutralized the same amount of toxin. When combined, the antibodies had additive neutralization efficacy. IQNPA binds to domain IV of PA containing the host cell receptor binding site, while IQNLF recognizes domain I containing the PA binding region in LF. A single 180-µg dose of either antibody given to A/J mice 2.5 h before challenge conferred 100% protection against a lethal intraperitoneal spore challenge with 24 50% lethal doses [LD50s] of B. anthracis Sterne and against rechallenge on day 20 with a more aggressive challenge dose of 41 LD50s. Mice treated with either antibody and infected with B. anthracis Sterne developed detectable murine anti-PA and anti-LF immunoglobulin G antibody responses by day 17 that were dependent on which antibody the mice had received. Based on these results, IQNPA and IQNLF act independently during prophylactic anthrax treatment and do not interfere with the establishment of endogenous immunity.

* Corresponding author. Mailing address: Biological Defense Research Directorate, Naval Medical Research Center, 12300 Washington Ave., Silver Spring, MD 20910-7500. Phone: (301) 231-6716. Fax: (301) 231-6799. E-mail: albrechtm{at}nmrc.navy.mil

{triangledown} Published ahead of print on 23 July 2007.

Editor: D. L. Burns

Infection and Immunity, November 2007, p. 5425-5433, Vol. 75, No. 11
0019-9567/07/$08.00+0     doi:10.1128/IAI.00261-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Oscherwitz, J., Yu, F., Cease, K. B. (2009). A Heterologous Helper T-Cell Epitope Enhances the Immunogenicity of a Multiple-Antigenic-Peptide Vaccine Targeting the Cryptic Loop-Neutralizing Determinant of Bacillus anthracis Protective Antigen. Infect. Immun. 77: 5509-5518 [Abstract] [Full Text]  
  • Nguyen, M. L., Terzyan, S., Ballard, J. D., James, J. A., Farris, A. D. (2009). The Major Neutralizing Antibody Responses to Recombinant Anthrax Lethal and Edema Factors Are Directed to Non-Cross-Reactive Epitopes. Infect. Immun. 77: 4714-4723 [Abstract] [Full Text]  
  • Chen, Z., Moayeri, M., Crown, D., Emerson, S., Gorshkova, I., Schuck, P., Leppla, S. H., Purcell, R. H. (2009). Novel Chimpanzee/Human Monoclonal Antibodies That Neutralize Anthrax Lethal Factor, and Evidence for Possible Synergy with Anti-Protective Antigen Antibody. Infect. Immun. 77: 3902-3908 [Abstract] [Full Text]  
  • Chen, Z., Moayeri, M., Zhao, H., Crown, D., Leppla, S. H., Purcell, R. H. (2009). Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc. Natl. Acad. Sci. USA 106: 13487-13492 [Abstract] [Full Text]  
  • Oscherwitz, J., Yu, F., Jacobs, J. L., Liu, T.-H., Johnson, P. R., Cease, K. B. (2009). Synthetic Peptide Vaccine Targeting a Cryptic Neutralizing Epitope in Domain 2 of Bacillus anthracis Protective Antigen. Infect. Immun. 77: 3380-3388 [Abstract] [Full Text]  
  • Mohamadzadeh, M., Duong, T., Sandwick, S. J., Hoover, T., Klaenhammer, T. R. (2009). Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. USA 106: 4331-4336 [Abstract] [Full Text]  
  • Nguyen, M. L., Crowe, S. R., Kurella, S., Teryzan, S., Cao, B., Ballard, J. D., James, J. A., Farris, A. D. (2009). Sequential B-Cell Epitopes of Bacillus anthracis Lethal Factor Bind Lethal Toxin-Neutralizing Antibodies. Infect. Immun. 77: 162-169 [Abstract] [Full Text]  
  • Lisanby, M. W., Swiecki, M. K., Dizon, B. L. P., Pflughoeft, K. J., Koehler, T. M., Kearney, J. F. (2008). Cathelicidin Administration Protects Mice from Bacillus anthracis Spore Challenge. J. Immunol. 181: 4989-5000 [Abstract] [Full Text]  
  • Moayeri, M., Robinson, T. M., Leppla, S. H., Karginov, V. A. (2008). In Vivo Efficacy of {beta}-Cyclodextrin Derivatives against Anthrax Lethal Toxin. Antimicrob. Agents Chemother. 52: 2239-2241 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»